Caplan Jay David 4
4 · Fractyl Health, Inc. · Filed Feb 8, 2024
Insider Transaction Report
Form 4
Caplan Jay David
President, Chief Product Off.
Transactions
- Conversion
Series C-2 Preferred Stock
2024-02-06−32,514→ 0 total(indirect: By Trust)→ Common Stock (15,150 underlying) - Conversion
Series B Preferred Stock
2024-02-06−177,726→ 0 total(indirect: By Trust)→ Common Stock (82,817 underlying) - Conversion
Common Stock
2024-02-06+23,299→ 358,806 total(indirect: By Trust) - Conversion
Series A Preferred Stock
2024-02-06−50,000→ 0 total(indirect: By Trust)→ Common Stock (23,299 underlying) - Conversion
Series C-1 Preferred Stock
2024-02-06−44,730→ 0 total(indirect: By Trust)→ Common Stock (20,843 underlying) - Conversion
Common Stock
2024-02-06+118,810→ 118,810 total(indirect: By Trust)
Footnotes (2)
- [F1]In connection with the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into common stock in accordance with the terms of such preferred stock.
- [F2]The Reporting Person's Form 3 filed on February 1, 2024 inadvertently omitted the securities held by the Jay D. Caplan 2021 Irrevocable Trust.